What ProMIS Neurosciences Inc. does.

ProMIS has in-licensed a patented technology platform with the potential to deliver a portfolio of antibody therapies, therapeutic vaccines, and other therapies derived from antibodies for neurodegenerative diseases and other misfolded protein diseases, which may include Alzheimer’s disease, multiple system atrophy, amyotrophic lateral sclerosis, frontotemporal lobar degeneration, Parkinson’s disease, progressive supranuclear palsy, corticobasal degeneration (respectively, AD, MSA, ALS, FTLD, PD, PSP, CBD) and schizophrenia. A common biologic cause contributes to each of these conditions, in that certain proteins, which normally perform a needed function, when misfolded, can cause neuronal degeneration and death, contributing to morbidity and mortality. ProMIS’ technology platform is an example of the advances in drug discovery enabled by computational power, in silico discovery, and/or artificial intelligence. We believe this platform provides a potential advantage by selectively targeting the toxic misfolded proteins with therapeutics.

ProMIS’ scientific foundation is centered on the growing knowledge base relating to diseases characterized by the presence of abnormal, misfolded proteins. Genetic and experimental research in the neuroscience community has demonstrated that propagating, neurotoxic, misfolded proteins (also referred to as prion-like particles or toxic soluble oligomers) are fundamental drivers of multiple neurodegenerative diseases, including AD, MSA, and ALS. ProMIS’ EpiSelect TM platform technology allows for the identification of conformational epitopes that become exposed on toxic, misfolded forms of a given protein but are not present on the properly folded form of the same protein. Such disease-specific epitopes (DSEs) can then be used to generate therapeutic antibody candidates that selectively target toxic forms of the protein without interfering with essential functions of the healthy protein.

Revenue and profit, by fiscal year.

More on PMN.

• ProMIS Neurosciences Inc. summary
• ProMIS Neurosciences Inc. financial statements
• ProMIS Neurosciences Inc. key metrics
• ProMIS Neurosciences Inc. health scores and style box
• ProMIS Neurosciences Inc. earnings
• ProMIS Neurosciences Inc. dividends
• ProMIS Neurosciences Inc. valuation
• ProMIS Neurosciences Inc. ownership and insiders
• ProMIS Neurosciences Inc. peers

Figures from ProMIS Neurosciences Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.